157 related articles for article (PubMed ID: 30850839)
1. BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL Strains.
Weaver JL; Zadrozny LM; Gabrielson K; Semple KM; Shea KI; Howard KE
Toxicol Sci; 2019 May; 169(1):194-208. PubMed ID: 30850839
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody.
Katano I; Hanazawa A; Otsuka I; Yamaguchi T; Mochizuki M; Kawai K; Ito R; Goto M; Kagawa T; Takahashi T
Sci Rep; 2021 Oct; 11(1):21087. PubMed ID: 34702924
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome.
Yan H; Semple KM; Gonzaléz CM; Howard KE
Transl Res; 2019 Aug; 210():43-56. PubMed ID: 31082370
[TBL] [Abstract][Full Text] [Related]
6. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
7. PD-1 checkpoint inhibition: Toxicities and management.
Hahn AW; Gill DM; Agarwal N; Maughan BL
Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.
Radaelli E; Hermans E; Omodho L; Francis A; Vander Borght S; Marine JC; van den Oord J; Amant F
PLoS One; 2015; 10(5):e0124974. PubMed ID: 25996609
[TBL] [Abstract][Full Text] [Related]
9. Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice.
Willis E; Verrelle J; Banerjee E; Assenmacher CA; Tarrant JC; Skuli N; Jacobson ML; O'Rouke DM; Binder ZA; Radaelli E
Vet Pathol; 2024 Jan; ():3009858231222216. PubMed ID: 38197423
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced aplastic anemia: A case report and literature review.
Comito RR; Badu LA; Forcello N
J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
[TBL] [Abstract][Full Text] [Related]
11. Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy.
Smith DJ; Lin LJ; Moon H; Pham AT; Wang X; Liu S; Ji S; Rezek V; Shimizu S; Ruiz M; Lam J; Janzen DM; Memarzadeh S; Kohn DB; Zack JA; Kitchen SG; An DS; Yang L
Stem Cells Dev; 2016 Dec; 25(24):1863-1873. PubMed ID: 27608727
[TBL] [Abstract][Full Text] [Related]
12. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.
Sun L; Li CW; Chung EM; Yang R; Kim YS; Park AH; Lai YJ; Yang Y; Wang YH; Liu J; Qiu Y; Khoo KH; Yao J; Hsu JL; Cha JH; Chan LC; Hsu JM; Lee HH; Yoo SS; Hung MC
Cancer Res; 2020 Jun; 80(11):2298-2310. PubMed ID: 32156778
[TBL] [Abstract][Full Text] [Related]
13. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice).
Watanabe Y; Takahashi T; Okajima A; Shiokawa M; Ishii N; Katano I; Ito R; Ito M; Minegishi M; Minegishi N; Tsuchiya S; Sugamura K
Int Immunol; 2009 Jul; 21(7):843-58. PubMed ID: 19515798
[TBL] [Abstract][Full Text] [Related]
14. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
Kamimura N; Wolf AM; Iwai Y
J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
[TBL] [Abstract][Full Text] [Related]
15. Induction of human humoral immune responses in a novel HLA-DR-expressing transgenic NOD/Shi-scid/γcnull mouse.
Suzuki M; Takahashi T; Katano I; Ito R; Ito M; Harigae H; Ishii N; Sugamura K
Int Immunol; 2012 Apr; 24(4):243-52. PubMed ID: 22402880
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
17. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
18. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
19. HIV Replication in Humanized IL-3/GM-CSF-Transgenic NOG Mice.
Perdomo-Celis F; Medina-Moreno S; Davis H; Bryant J; Zapata JC
Pathogens; 2019 Mar; 8(1):. PubMed ID: 30871027
[TBL] [Abstract][Full Text] [Related]
20. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
[Next] [New Search]
